Delcath Systems (NASDAQ:DCTH) Stock Rating Upgraded by StockNews.com

Delcath Systems (NASDAQ:DCTH) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Friday.

Several other research firms also recently commented on DCTH. Stephens reissued an “overweight” rating and set a $25.00 target price on shares of Delcath Systems in a research report on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of Delcath Systems in a report on Tuesday, August 6th. Finally, Craig Hallum began coverage on Delcath Systems in a report on Friday, June 28th. They issued a “buy” rating and a $18.00 target price for the company. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $21.50.

Delcath Systems Trading Up 0.1 %

Shares of NASDAQ:DCTH opened at $7.50 on Friday. The firm has a market cap of $208.40 million, a price-to-earnings ratio of -2.83 and a beta of 0.64. Delcath Systems has a 1 year low of $2.25 and a 1 year high of $9.18. The business has a fifty day simple moving average of $7.96 and a 200 day simple moving average of $6.18.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.12). The firm had revenue of $7.77 million for the quarter, compared to analysts’ expectations of $5.00 million. Delcath Systems had a negative return on equity of 290.07% and a negative net margin of 1,080.72%. During the same period last year, the business earned ($0.58) earnings per share. On average, sell-side analysts forecast that Delcath Systems will post -1.31 EPS for the current year.

Hedge Funds Weigh In On Delcath Systems

A number of hedge funds have recently made changes to their positions in the business. Levin Capital Strategies L.P. lifted its position in shares of Delcath Systems by 12.2% during the 1st quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock worth $262,000 after buying an additional 5,969 shares during the period. Marshall Wace LLP raised its stake in Delcath Systems by 7.0% during the second quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock worth $776,000 after acquiring an additional 6,066 shares in the last quarter. AIGH Capital Management LLC lifted its holdings in shares of Delcath Systems by 1.7% during the second quarter. AIGH Capital Management LLC now owns 2,399,792 shares of the company’s stock valued at $20,086,000 after acquiring an additional 40,064 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Delcath Systems in the 2nd quarter valued at $370,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Delcath Systems in the 2nd quarter worth about $694,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.